CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $3.12B, above the global median of $1.15B
- FinancialsAltman Z-Score 4.19: safe zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
21.02BCNY3.12B · vs all stocks (USD)
Trailing P/E
261.90xRevenue (TTM)
955.53MCNY141.92M · vs all stocks (USD)
Profit Margin
9.89%Beta
0.7150xvs all stocks
52-Week Change
-20.53%vs all stocks
Market Capitalization
21.02BCNY3.12B · vs all stocks (USD)
Enterprise Value
25.00BCNY3.71B · vs all stocks (USD)
Trailing P/E
261.90xForward P/E
87.30xPrice to Sales (TTM)
24.21xPrice to Book (MRQ)
31.18xEnterprise to Revenue
26.16xEnterprise to EBITDA
82.35xGross Margin
64.90%Profit Margin
9.89%Operating Margin
37.98%Return on Assets (TTM)
3.46%Return on Equity (TTM)
12.92%Revenue (TTM)
955.53MCNY141.92M · vs all stocks (USD)
Revenue per Share (TTM)
1.03CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-3.50%Gross Profit (TTM)
551.37MCNY81.89M · vs all stocks (USD)
EBITDA (TTM)
408.03MCNY60.60M · vs all stocks (USD)
Net Income (TTM)
94.52MCNY14.04M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
82.90%Operating Cash Flow (TTM)
263.91MCNY39.20M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-137.90MCNY-20.48M · vs all stocks (USD)
Payout Ratio
0.00%Minority Interest (Equity)
15.98MCNYFY2025 · Dec 31, 2025Revenue
966.35MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
402.36MCNYFY2025 · Dec 31, 2025Gross Profit
564.00MCNYFY2025 · Dec 31, 2025Operating Income
218.53MCNY32.46M · vs all stocks (USD)
Pre-tax Income
64.23MCNYFY2025 · Dec 31, 2025Income Tax Expense
30.20MCNYFY2025 · Dec 31, 2025Net Income
34.03MCNYFY2025 · Dec 31, 2025EBIT
162.27MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
333.06MCNYFY2025 · Dec 31, 2025Research & Development
126.85MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
117.40MCNYFY2025 · Dec 31, 2025Other Operating Expenses
17.99MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
559.48KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
98.04MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0400CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
914.25MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
914.25MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
34.03MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.54MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
62.17MCNYFY2025 · Dec 31, 2025Free Cash Flow
-171.75MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
77.28MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
34.03MCNYFY2025 · Dec 31, 2025Other Non-cash Items
105.17MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-49.51MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-27.52MCNYFY2025 · Dec 31, 2025Capital Expenditures
-233.92MCNYFY2025 · Dec 31, 2025Net Acquisitions
1.85MCNYFY2025 · Dec 31, 2025Purchase of Investments
-442.85KCNYFY2025 · Dec 31, 2025Sale of Investments
5.84MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-226.67MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.58BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.64BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-94.84MCNYFY2025 · Dec 31, 2025Other Financing Charges
130.57MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-23.96MCNYFY2025 · Dec 31, 2025Shares Outstanding
883.24MSharesUpdated Aug 19, 2026Float Shares
643.98MSharesUpdated Aug 19, 2026% Held by Insiders
23.31%vs all stocks
% Held by Institutions
1.44%vs all stocks
Total Cash (MRQ)
108.74MCNY16.15M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.1230CNYUpdated Aug 19, 2026Total Debt (MRQ)
1.96BCNY291.01M · vs all stocks (USD)
Total Debt to Equity (MRQ)
2.59xCurrent Ratio (MRQ)
0.4290xBook Value per Share (MRQ)
0.8400CNYUpdated Aug 19, 2026Total Assets
3.15BCNY468.43M · vs all stocks (USD)
Total Current Assets
523.56MCNYFY2025 · Dec 31, 2025Total Liabilities
2.52BCNYFY2025 · Dec 31, 2025Total Non-current Assets
2.63BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
742.32MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.78BCNYFY2025 · Dec 31, 2025Cash
77.11MCNYFY2025 · Dec 31, 2025Cash Equivalents
23.61MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
100.72MCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.23MCNYFY2025 · Dec 31, 2025Accounts Receivable
121.55MCNYFY2025 · Dec 31, 2025Inventory
261.38MCNYFY2025 · Dec 31, 2025Accounts Payable
261.97MCNYFY2025 · Dec 31, 2025Short-term Debt
1.28BCNYFY2025 · Dec 31, 2025Other Current Liabilities
14.92MCNYFY2025 · Dec 31, 2025Long-term Debt
623.40MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
2.32MCNYFY2025 · Dec 31, 2025Common Stock (Book)
883.24MCNYFY2025 · Dec 31, 2025Retained Earnings
-1.81BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
629.93MCNY93.56M · vs all stocks (USD)
52-Week Low
16.23CNYUpdated Aug 19, 202652-Week High
30.70CNYUpdated Aug 19, 202652-Week Change
-20.53%vs all stocks
Beta
0.7150xvs all stocks
50-Day MA
22.76CNYUpdated Aug 19, 2026200-Day MA
20.47CNYUpdated Aug 19, 2026Avg 10-Day Volume
62.58MSharesUpdated Aug 19, 2026Avg 30-Day Volume
58.13MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.1000CNYUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 24.21Revenue Growth YoY: -0.04
Financial Health
Altman Z-Score 4.19: safe zoneNotable
Altman Z-Score: 4.19
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $3.12B, above the global median of $1.15BNotable
Market cap (USD): 3,122,060,276.582Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
BioArctic AB
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Haoyuan Chemexpress Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Kanghong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Aodong Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
ABL Bio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Betta Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Integer Holdings Corporation
Tier 1ProductionApproval-Gated PipelineRule
Wockhardt Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
MBX Biosciences, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Walvax Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule